Among the highlights of 3 recent studies: insights into hormonal risk factors for rheumatoid arthritis.
Highlights of 3 recent studies that can affect your practice: a novel procedure for knee pain, cardiovascular risk in RA, and febuxostat in early gout.
A green light for dosing to achieve the target urate level.
To paraphrase Winston Churchill, rarely have so few been called upon by so many.
Complaints about loss of self, loss of role identity, and lower quality of life dominate within this patient population.
Cardiovascular disease prevention and treatment strategies for patients with diabetes may apply.
A systematic review suggests that overweight and obese patients with gout can benefit from shedding pounds.
This is the first FDA-approved fixed-dose combination treatment that addresses both overproduction and underexcretion of serum uric acid in a single pill.
The latest recommendations emphasize providing key information about the disease and its treatment.
This noninvasive modality may be used to investigate joint damage and distinguish between asymptomatic conditions.